NFE2L2
NFE2L2 (Nuclear factor erythroid 2-related factor 2) is a protein that switches other genes on and off. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 5 more. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Biology
Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralising reactive electrophiles. In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex. In response to oxidative stress, electrophile metabolites inhibit activity of the BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2, heterodimerisation with one of the small Maf proteins and binding to ARE elements of cytoprotective target genes. The NFE2L2/NRF2 pathway is also activated in response to selective autophagy: autophagy promotes interaction between KEAP1 and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex, leading to NFE2L2/NRF2 nuclear accumulation and expression of cytoprotective genes. The NFE2L2/NRF2 pathway is also activated during the unfolded protein response (UPR), contributing to redox homeostasis and cell survival following endoplasmic reticulum stress. May also be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region. Location: Cytoplasm, cytosol; Nucleus (UniProt). Locus 2q31.2 (HGNC).
- Lung cancer: Open Targets association 0.71 with lung cancer (MONDO_0008903)
- Hepatocellular carcinoma: Open Targets association 0.61 with hepatocellular carcinoma (MONDO_0007256); IntOGen driver in 4 cohorts (HCC)
- Head and neck squamous cell carcinoma: Open Targets association 0.62 with head and neck squamous cell carcinoma (MONDO_0010150); IntOGen driver in 2 cohorts (HNSC)
- Bladder & urothelial cancer: Open Targets association 0.55 with urinary bladder cancer (MONDO_0001187); IntOGen driver in 3 cohorts (BLCA)
- Oesophageal cancer: Open Targets association 0.60 with oesophageal cancer (MONDO_0007576); IntOGen driver in 1 cohort (ESCA)
- Endometrial cancer: Open Targets association 0.54 with endometrial cancer (MONDO_0011962); IntOGen driver in 1 cohort (UCEC)
External identifiers
Built from HGNC, Ensembl, UniProt and ChEMBL idsProducts by modality and phase
Browse products →No product in the corpus is aimed at this target yet.
Trials
Evidence ranking →No trial in the corpus names this target or one of its products.
Resistance routes
Unaddressed routes →The resistance atlas has no route that names this target.
Pathways
Pathway-to-drug matrix →No pathway diagram carries this target as a node.
Companion diagnostics
Assay registry →No companion diagnostic in the registry measures this target.
Preclinical models
All models →No model entry for this target yet; check the cancer entries on the models page.
Open questions
All open questions →No open questions recorded for this target yet. Suggest one.
Literature
Preprints →Query for this target: (TITLE:"NFE2L2" OR ABSTRACT:"NFE2L2" OR TITLE:"NFE2 like bZIP transcription factor 2" OR ABSTRACT:"NFE2 like bZIP transcription factor 2" OR TITLE:"Nuclear factor erythroid 2-related factor 2" OR ABSTRACT:"Nuclear factor erythroid 2-related factor 2" OR TITLE:"NRF2" OR ABSTRACT:"NRF2" OR TITLE:"NRF-2" OR ABSTRACT:"NRF-2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NFE2L2, not a curated reading list.
Export
The dossier as machine-readable JSON: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/nfe2l2.json. Licence CC BY-NC 4.0.